Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis
Trent P. Wang,Kwang W. Ahn,Mazyar Shadman,Manmeet Kaur,Nausheen Ahmed,Ulrike Bacher,Jan Cerny,Andy Chen,Narendranath Epperla,Matthew Frigault,Natalie Grover,Bradley Haverkos,Brian Hill,Nasheed Hossain,Madiha Iqbal,Tania Jain,Maxwell M. Krem,Joseph Maakaron,Dipenkumar Modi,Muhamad Alhaj Moustafa,Peter Riedell,Bipin Savani,R. Alejandro Sica,Anna Sureda,Kitsada Wudhikarn,Alex F. Herrera,Craig Sauter,Mehdi Hamadani,Antonio Jimenez Jimenez
DOI: https://doi.org/10.1038/s41375-024-02242-6
2024-05-16
Leukemia
Abstract:CD19 CAR T-cell (CAR-T) therapy is commonly administered to patients with relapsed or refractory large B-cell lymphomas (LBCL), but salvage or bridging therapy can sometimes lead to a complete response (CR) prior to infusion. Limited studies have assessed the outcomes of patients infused in CR. A total of 134 patients with LBCL in CR prior to CAR-T infusion were identified from the CIBMTR registry, with median prior lines of therapy of 3 (range 2–9). At two years post-infusion, the probability of progression-free survival was 43.5% (95% CI 34.4–52.8) and the probability of overall survival was 63.8% (95% CI 54.4–72.6). The cumulative incidence rates of non-relapse mortality and relapse/progression at two years were 9.2% (95% CI 4.5–15.4) and 47.3% (95% CI 38.2–56.6), respectively. The rate of grade 3 or higher cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were 2.2% and 8.2%, respectively. In summary, CAR-T in heavily pretreated patients with LBCL who are in CR following two or more lines of prior therapy demonstrate that a subset of patients may remain free of progression at two years. Additionally, the toxicity profile was impressive with very low rates of grade 3 CRS and ICANS.
oncology,hematology